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ABSTRACT
Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase 
(PARP)-1/-2 inhibitor approved for maintenance treatment of both BRCA mutant 
(mut) and BRCA wildtype (wt) adult patients with recurrent epithelial ovarian, 
fallopian tube, or primary peritoneal cancers who have demonstrated a complete 
or partial response to platinum-based chemotherapy. In patients without germline 
BRCA mutations (non-gBRCAmut), niraparib improved progression-free survival (PFS) 
by 5.4 months, whereas another PARP inhibitor (PARPi) olaparib supplied only 1.9 
months of improvement in a similar patient population. Previous studies revealed 
higher cell membrane permeability and volume of distribution (VD) as unique features 
of niraparib in comparison to other PARPi including olaparib. Here, we explore the 
potential correlation of these pharmacokinetic properties to preclinical antitumor 
effects in BRCAwt tumors. Our results show that at steady state, tumor exposure to 
niraparib is 3.3 times greater than plasma exposure in tumor xenograft mouse models. 
In comparison, the tumor exposure to olaparib is less than observed in plasma. In 
addition, niraparib crosses the blood-brain barrier and shows good sustainability 
in the brain, whereas sustained brain exposure to olaparib is not observed in the 
same models. Consistent with its favorable tumor and brain distribution, niraparib 
achieves more potent tumor growth inhibition than olaparib in BRCAwt models and 
an intracranial tumor model at maximum tolerated doses (MTD). These findings 
demonstrate favorable pharmacokinetic profiles and potent antitumor effects of 
niraparib in BRCAwt tumors, consistent with its broader clinical effect in patients 
with both BRCAmut and BRCAwt tumors.
INTRODUCTION
PARP1 and 2 are key enzymes acting as DNA 
damage sensors and signal transducers in response to 
DNA damage. PARP binds to DNA sites with single-
strand breaks (SSBs), catalyzes the poly(ADP-ribosyl)
ation (PARylation) of target proteins and recruits DNA 
repair proteins to these sites [1–4]. Consistent with 
the importance of PARP in DNA repair, inhibition of 
PARP activity in homologous recombination (HR)-
deficient cells (such as those with BRCA and PALB2 
mutations) induces cell death due to a mechanism known 
as ‘synthetic lethality’, as it is difficult for cancer cells 
to tolerate simultaneous loss of both PARP-dependent 
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SSB repair and HR-mediated double-strand break (DSB) 
repair machinery. This important observation led to the 
pharmaceutical development of PARP inhibitors (PARPi) 
[5–7]. Currently, at least 6 PARPi are being evaluated 
actively in clinical settings in a variety of cancer types.
Clinical development of PARPi is most advanced 
in ovarian cancers (OC), the most common cause of 
gynecologic cancer death in the United States with 22,000 
newly diagnosed cases each year [8]. The majority of 
High Grade Serous Ovarian Cancer (HGSOC), the most 
aggressive subtype of OC, are characterized by DNA 
repair deficiency. Approximately 40-50% of HGSOC 
have some level of genetic or epigenetic alterations in 
HR repair pathways including mutations in BRCA1/2, 
Fanconi anemia genes, core HR genes, DNA damage 
response genes and epigenetic silencing of BRCA1 via 
promoter hypermethylation [9–16]. In addition, about 
one-third of HGSOC cases are possibly HR deficient 
with alterations in non-bona fide HR genes, such as 
PTEN loss, EMSY amplification, CDK12 mutations, and 
overexpression of specific miRNAs [9, 17–21]. Therefore, 
it has been estimated that only approximately 15% of 
HGSOC, such as cancers with cyclin E amplification, are 
HR proficient [16]. Even though the majority of HGSOC 
are considered HR deficient, individual sensitivities to 
PARPi are different, perhaps due to differing degrees 
of HR deficiency influenced by genetic and epigenetic 
alterations. For example, Murai and colleagues showed 
that BRCA1/2 or XRCC2/3 mutant cells are more sensitive 
to PARPi treatment in vitro than RAD54, FANCC, or 
POLH/Z mutant cells by 1 to 2 orders of magnitude 
[22], indicating that for a PARPi to be efficacious, 
higher concentration of drug is required in BRCAwt than 
BRCAmut tumors.
Olaparib is the first FDA approved PARPi for 
BRCAmut OC, whereas niraparib is the first PARPi 
demonstrating clinical effect in both BRCAwt and 
BRCAmut OC, and approved for maintenance treatment 
based on data from the large Phase 3, double-blinded 
NOVA trial enrolled patients with recurrent OC responsive 
to platinum therapies. In the NOVA trial, not only the 
median duration of progression-free survival (mPFS) 
improved by 15.5 months (from 5.5 to 21.0 months) 
in patients with germline BRCA (gBRCA) mutation, 
but the mPFS of patient without gBRCA mutation also 
improved by 5.4 months (from 3.9 to 9.3 months) [23]. 
In a similar population of BRCAwt patients, olaparib 
provided a 1.9-month improvement in mPFS (from 5.5 to 
7.4 months) in a randomized Phase 2 trial, Study 19 [24]. 
The mechanism of action of these two PARPi, which could 
potentially explain the different clinical effects in BRCAwt 
OC, has yet to be explored.
The anti-tumor effect of PARPi has been attributed 
to their ability to inhibit DNA repair and to trap PARP 
on DNA and ultimately induce DSB formation, with the 
former mechanism thought to be more HR deficiency-
specific [22, 25–28]. The PARP inhibition potency and 
PARP trapping ability of niraparib and olaparib are 
similar in cell-free systems established using recombinant 
proteins [22, 26, 29]. In cultured cancer cells, niraparib 
is approximately twice as potent as olaparib in trapping 
PARP onto DNA [22, 30]. Similarly, their abilities to 
induce S-phase-specific DNA damage response and cancer 
cell death are also different with niraparib being a few 
fold more potent than olaparib in both BRCA mutant and 
wildtype cells [22, 30–32]. One potential explanation is 
different cell membrane permeabilities of the two drugs, as 
the apparent permeability coefficient (Papp) of niraparib 
(12 to 18 × 106 cm/s) is higher than that of olaparib (3 to 
9 × 106 cm/s) [33, 34]. In addition to low permeability, 
olaparib has a very low solubility in aqueous solutions 
and therefore is classified as Class IV drug according to 
the Biopharmaceutical Classification System (BCS)[35, 
36], whereas niraparib is a BCS Class I (high permeability 
and high solubility) or Class II (high permeability and 
low solubility) drug when administered at 200 or 300 mg 
in humans, respectively [34]. The volume of distribution 
(VD) for niraparib (≈1220 L) is also higher than that of 
olaparib (≈158 L) in humans at steady state [37, 38], 
indicating a potential higher tendency of niraparib to 
concentrate in the peripheral body compartment including 
solid tumors rather than in plasma. Indeed, in a Phase 
1 study of 60 patients with invasive breast cancer, the 
average tumor concentration of olaparib was 41% of the 
plasma concentration [39], potentially attributed to its 
low VD. The tumor exposure to niraparib has not yet been 
reported in clinical settings.
To explore whether the biophysical properties 
intrinsic to niraparib, such as high permeability and VD, 
may contribute to its broader clinical activity in patients 
with or without BRCA mutations, the pharmacokinetic 
profiles and efficacies of niraparib and olaparib were 
compared in preclinical tumor models. Our results show 
that niraparib tumor exposure is significantly higher than 
plasma exposure, which is consistent with its high VD. In 
comparison, olaparib tumor exposure is lower than plasma 
exposure. In addition, niraparib permeates the brain, 
whereas olaparib shows very limited brain exposure at 
maximum tolerated dose (MTD). Importantly, in BRCAwt 
tumor xenograft models and an intracranial tumor model, 
niraparib achieved more potent tumor growth inhibition 
than olaparib.
RESULTS
Niraparib preferentially concentrates in tumor 
compared to plasma and penetrates the blood-
brain barrier
To understand the difference in pharmacokinetic 
profiles, exposure to niraparib and olaparib was evaluated 
in tumor, plasma and other body tissues collected from 
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both ovarian and breast cancer xenograft models. The 
treatment doses and schedules were defined based on 
the MTD in each model, as previously reported [40] or 
determined in the models used in this study.
Tumor, brain, bone marrow, muscle, and plasma 
exposure to niraparib and olaparib were measured in 
samples collected from NOD/SCID mice orthotopically 
inoculated with BRCA1mut MDA-MB-436 triple-negative 
breast cancer (TNBC) cells and treated with 75 mg/kg of 
niraparib once daily (qd) or olaparib (100 mg/kg qd) for 5 
days. The time of maximum concentration observed (tmax), 
observed mean of maximum concentration (Cmax) and the 
WinNonlin calculated area under the curve (AUC0-24h) 
of niraparib at steady state were all significantly higher 
than those of olaparib in all tissue types tested, despite 
the fact that the daily dose of niraparib was lower in this 
BRCA1mut model (Figure 1A–1E; Table 1). The dose-
normalized exposure to niraparib was 10-, 51-, and 100-
fold higher than that to olaparib in plasma, tumor, and 
brain, respectively (Table 1).
Although tissue distribution of a drug often largely 
depends on its physicochemical characteristics, the 
abnormal vasculature, reactive stroma, and inflammation 
that characterize the tumor microenvironment may 
affect drug penetration [41]. Therefore, tissue and 
plasma exposure to niraparib and olaparib were also 
measured in samples collected from BALB/c nude mice 
subcutaneously implanted with the BRCAwt OVC134 
ovarian tumor fragment and treated with niraparib (50 mg/
kg qd) or 67 mg/kg of olaparib twice a day (bid) for 2 days 
at MTDs previously determined in this model. Similar 
to results obtained from the BRCAmut TNBC xenograft 
model, niraparib demonstrated superior exposure over 
olaparib in all tissue types tested in this BRCAwt ovarian 
cancer xenograft model, although again niraparib was 
administered with a lower daily dose than olaparib 
(Supplementary Figure 1A–1C; Table 2). The dose-
normalized exposure to niraparib was 3-, 16-, and 34-fold 
higher than that to olaparib in plasma, tumor, and brain, 
respectively (Table 2). The results from both xenograft 
models consistently demonstrate significantly higher 
exposure to niraparib in all tissue types tested including 
plasma, tumor, and brain regardless of the differences in 
BRCA status, tumor type or host strain of mice.
The tissue distribution of niraparib and olaparib 
were also compared in both the MDA-MB-436 and 
OVC134 models. After 5-day treatment in the MDA-
MB-436 model or 2-day treatment in the OVC134 
model, niraparib tumor exposure was 3.3-fold of plasma 
exposure (Figure 2A & 2C and Table 3), suggesting that 
Figure 1: Steady state pharmacokinetics (PK) of niraparib and olaparib in tumor, brain, bone marrow, muscle, and 
plasma. (A) Tumor, (B) Brain, (C) Bone marrow, (D) Muscle, and (E) Plasma PK in the BRCA1mut MDA-MB-436 TNBC xenograft 
model treated with niraparib or olaparib at the maximum tolerated dose. Niraparib and olaparib were administered orally at 75 and 100 
mg/kg qd, respectively. All mice were treated for 5 days, and samples were collected on the last day of treatment at pre-dose and 1, 2, 4, 
8, 12, and 24 hours post dose for niraparib and at pre-dose and 0.5, 1, 2, 6, 12, and 24 hours post dose for olaparib. LLOQ=lower limit of 
quantification.
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niraparib tends to concentrate in tumor relative to plasma. 
In comparison, the tumor exposure to olaparib was only 
0.6- to 0.7-fold of plasma exposure in the same studies 
regardless of the once daily or twice daily dosing schedule 
(Figure 2B & 2D and Table 3).
The brain exposure to these 2 drugs was also 
significantly different. In both tumor models, the brain 
to plasma exposure (AUC) ratio of niraparib was ≈0.3, 
whereas that of olaparib was ≈0.03 (Table 3). While the 
exposure to niraparib in brain was highly sustainable, 
olaparib was detectable in brain only for the first 6 hours 
following drug administration in both MDA-MB-436 
(Figure 1B) and OVC134 (Supplementary Figure 
1B) models. Because the brain exposure to a drug is 
regulated by ABC (efflux) transporters, such as BCRP or 
P-glycoprotein (P-gp, MDR1) which are highly expressed 
at the blood-brain barrier (BBB), the efflux rates of both 
PARPi were compared in cells overexpressing these 
transporters, to understand the potential cause of different 
brain exposures. Although both niraparib and olaparib 
are substrates of P-gp [38, 42, 43], the net efflux ratios 
of niraparib were approximately 2 to 5 times lower than 
those of olaparib at 3 different concentrations tested 
in the MDCKII cells overexpressing BCRP or P-gp 
(Supplementary Table 1). The low efflux rate of niraparib 
in this in vitro assay, which could potentially be attributed 
to its high bio-membrane permeability, may explain why 
niraparib could overcome ABC transporter-mediated 
efflux at the BBB and achieve significantly higher brain 
exposure than olaparib.
Together, these results demonstrate unique 
properties of niraparib including its ability to concentrate 
in tumor relative to plasma and to permeate the BBB, 
consistent with its high VD. Moreover, studying tumor 
exposure in addition to plasma exposure revealed 
profoundly distinct pharmacokinetic profiles in vivo for 
drugs of the same class.
Niraparib induces more potent tumor growth 
inhibition than olaparib in some BRCAwt tumor 
models
Because MTD administration of niraparib achieved 
significantly higher exposure in tumor than olaparib, we 
next evaluated whether there was any association between 
tumor exposure to PARPi and its growth inhibition. To 
compare the antitumor activities of niraparib and olaparib, 
these PARPi were evaluated in 2 commonly used ovarian 
cancer or breast cancer cell line-derived xenograft (CDX) 
models and 4 patient-derived xenograft (PDX) models.
The BRCA1mut MDA-MB-436 TNBC CDX model 
was treated with MTDs of niraparib or olaparib, with 
niraparib administered orally at 75 mg/kg qd for 28 days 
and olaparib administered orally at 75 mg/kg bid for 7 
days and then reduced to 67 mg/kg bid for the last 21 days 
due to body weight loss (Figure 3A). Both niraparib and 
olaparib achieved a similar degree of tumor regression in 
this model (Figure 3B), suggesting that the tumor exposure 
to both PARPi are above the exposure required to achieve 
their full anti-tumor response in this BRCAmut tumor 
model. Because BRCAmut tumors are highly sensitive 
to PARPi as previously reported in cultured cells [22], 
the required exposure to PARPi in the BRCAmut tumors 
may be lower than that in the less sensitive tumors. For 
this reason, we hypothesized that differences in efficacy 
might be revealed in BRCAwt models, where higher drug 
concentrations are required to induce tumor cell death.
To test this hypothesis, the antitumor effects of 
niraparib and olaparib were evaluated in 5 BRCAwt tumor 
models. The BRCAwt OVC134 ovarian cancer PDX 
model was treated with MTDs of niraparib or olaparib, 
with niraparib initially administered at 50 mg/kg and 
reduced to 40 mg/kg qd, and olaparib first administered 
at 67 mg/kg and reduced to 60 mg/kg bid, both due to 
body weight loss. Niraparib markedly reduced tumor 
Table 1: Steady State Tissue and Plasma PK of Niraparib and Olaparib in MDA-MB-436 TNBC Model
PARPi Tumor PK Brain PK Bone Marrow PK Muscle PK Plasma PK
Cmax
(μg/g)
tmax
(h)
AUC0-24h
(μg/g·h)
Dose
normalized
AUC0-24h
(μM·h/mg)
Cmax
(μg/g)
tmax
(h)
AUC0-24h
(μg/g·h)
Dose
normalized
AUC0-24h
(μM·h/mg)
Cmax
(μg/g)
tmax
(h)
AUC0-24h
(μg/g·h)
Dose
normalized
AUC0-24h
(μM·h/mg)
Cmax
(μg/g)
tmax
(h)
AUC0-24h
(μg/g·h)
Dose
normalized
AUC0-24h
(μM·h/mg)
Cmax
(μg/
mL)
tmax
(h)
AUC0-24h
(μg/
mL·h)
Dose
normalized
AUC0-24h
(μM·h/mg)
Niraparib
(75 mg/kg 
qd 5 days)
19.10 4 213.96 8.90 1.78 4 18.72 0.78 0.32 12 2.82 0.12 15.63 4 139.80 5.82 7.62 4 65.08 2.71
Olaparib
(100 mg/
kg qd 5 
days)
0.66 1 7.59 0.17 0.09 0.5 0.34 0.01 LLOQ ND LLOQ ND 0.51 1 3.29 0.08 1.77 1 11.28 0.26
Dose 
normalized
AUCnir/ola 
Ratio
- - - 51 - - - 100 - - - - - - - 77 - - - 10
AUC0–24h=area under the plasma concentration–time curve from 0 to 24 hours; LLOQ=lower limit of quantification; ND= not determined; nir=niraparib; ola=olaparib.
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growth with 58% tumor growth inhibition (TGI), whereas 
olaparib treatment had little effect (Figure 3C, 3D, & 
Supplementary Figure 2A).
The antitumor activities of niraparib and olaparib 
were then examined in the BRCAwt A2780 ovarian cancer 
CDX model, with niraparib and olaparib administered 
at 62.5 and 100 mg/kg once daily, respectively. Neither 
drug caused severe body weight loss or noticeable toxicity 
in this model (data not shown). Even though in cultured 
A2780 cells, the cytotoxicities induced by niraparib and 
olaparib were not statistically different (Supplementary 
Figure 3), the in vivo efficacy of these two PARPi were 
significantly different (P = 0.005) in this ovarian cancer 
CDX model established with the same cell line (Figure 
3E). Niraparib treatment induced significant tumor 
growth inhibition (TGI = 56.4%), whereas the effect of 
olaparib was minimal (TGI = 15.6%) and nonsignificant 
(Figure 3F, & Supplementary Figure 2B). One potential 
explanation of these results is that the tumor concentration 
of a drug is relatively more important when the sensitivity 
to the drug is moderate, such as in the BRCAwt OVC-134 
and A2780 tumors.
The antitumor activities of niraparib and olaparib 
were also examined in 3 additional BRCAwt ovarian 
cancer models, OVC527, OV5308 and OVCAR3, 
where both drugs showed similar degree of efficacy 
(Supplementary Figure 4). In OVC527 and OV5308 
models, both niraparib and olaparib induced similar 
degrees of tumor regression, suggesting that, similar to 
BRCAmut tumors, these BRCAwt but HR deficient tumors 
are also highly sensitive to PARPi. In contrast, both drugs 
had minimum antitumor effects in the OVCAR3 CDX 
model, perhaps due to lack of HR deficiency or inherent 
resistance to PARPi.
To better understand the pharmacodynamic effects 
of these PARPi in tumor, we attempted to correlate 
PARylation inhibition with antitumor effects in preclinical 
models. However, potent total PARylation inhibition (>85-
90% inhibition compared to vehicle control) was always 
observed over time regardless of efficacy for both PARPi 
in BRCAmut MDA-MB-436 and BRCAwt OVC134 
models (data not shown), suggesting that inhibition of 
total PARylation may not be a good biomarker for PARPi 
efficacy.
Taken together, these results demonstrate the 
antitumor effect of niraparib regardless of BRCA mutation 
status. This potent efficacy of niraparib may be related to 
its ability to concentrate in tumor relative to plasma, which 
might be particularly relevant in the setting of BRCAwt 
tumors.
Differential killing of niraparib versus olaparib 
in BRCAwt versus BRCAmut models
The observation of greater TGI in BRCAwt models 
with niraparib vs. olaparib might relate to greater tumor 
exposure resulting from better cell membrane penetration 
achieved with niraparib. We therefore assessed the 
minimal efficacious dose (MED) of niraparib required 
to induce efficacious tumor growth inhibition in both 
BRCAmut and BRCAwt models.
Niraparib was administered at 25, 50, or 75 mg/kg 
once daily for 28 days to mice bearing MDA-MB-436 
BRCAmut tumors. Suppression of tumor growth was 
observed at all doses with TGIs of 60%, 93%, and 107%, 
respectively (Figure 4A). In the OVC 134 ovarian model, 
administration of 20, 40, or 60 mg/kg of niraparib once 
daily for 32 days resulted in 4%, 21%, and 64% TGI, 
Table 2: Tissue and Plasma PK of Niraparib and Olaparib in OVC134 Ovarian PDX Model
PARPi Tumor PK Brain PK Plasma PK
Cmax
(μg/g)
tmax
(h)
AUC0-last
(μg/g·h)
Dose 
normalized
AUC0-24h 
(μM·h/mg)
Cmax
(μg/g)
tmax
(h)
AUC0-last
(μg/g·h)
Dose 
normalize
AUC0-24h 
(μM·h/mg)
Cmax
(μg/mL)
tmax
(h)
AUC0-last
(μg/
mL·h)
Dose 
normalized
AUC0-24h 
(μM·h/mg)
Niraparib
(50 mg/kg 
qd 2 days)
10.80 4 83.14 5.19 0.65 4 8.31 0.52 3.24 4 25.50 1.59
Olaparib
(67mg/kg 
bid 2 days)
6.17 0.5 9.73 0.33 0.52 0.5 0.45 0.02 15.04 0.5 15.59 0.53
Dose 
normalized
AUCnir/ola 
ratio
- - - 16 - - - 34 - - - 3
AUC0–last=area under the plasma concentration–time curve from 0 to the time of the last PK sampling post-dose, for 
niraparib AUC0–last is AUC0–24h, for olaparib AUC0–last is AUC0–12h; nir=niraparib; ola=olaparib.
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respectively. Only the 60 mg/kg dose level (reduced to 50 
mg/kg after 4 days of dosing due to body weight loss) 
was considered efficacious (Figure 4B), gauging upon the 
cutoff of ≥50% TGI. The MED of niraparib was estimated 
to be 10 mg/kg in the MDA-MB-436 BRCAmut model and 
53 mg/kg in the OVC134 BRCAwt model by extending 
the dose-response curve obtained through linear regression 
fitting (Figure 4C). Notably, the MED of the BRCAwt 
OVC134 tumors (53 mg/kg) is 5 fold greater than the 
MED for the BRCAmut MDA-MB-436 tumors (10 mg/
kg), suggesting, as expected, that tumors with different HR 
deficiency profiles have different sensitivities to PARPi. 
On the other hand, although olaparib was efficacious in 
the BRCAmut MDA-MB-436 model, it failed to induce 
a meaningful antitumor effect in the BRCAwt OVC134 
model (21% TGI) at MTD (150 mg/kg/day) (Figure 4C), 
suggesting that high tumor exposure and cell membrane 
permeability of niraparib may contribute to its potent 
antitumor effect in BRCAwt tumors.
Tumor response in a PDX model is improved 
when switching to niraparib from olaparib
An important question in cancer care is whether 
there will be any benefit in switching from one agent to 
another agent in the same drug class. Physicians face this 
question often, when drug efficacy is limited. To mimic 
this situation, we next tested the effect of sequential 
treatment with olaparib followed by niraparib in the 
BRCA2mut OV5311 ovarian cancer PDX model. When 
treated with niraparib or olaparib at 50 or 75 mg/kg qd, 
respectively, for 44 days, niraparib treatment resulted in 
complete tumor regression, whereas olaparib failed to 
induce tumor regression (Figure 5). On treatment day 
45, mice in the olaparib group were randomized to two 
treatment groups, switching to 50 mg/kg of niraparib 
(4/9 mice with the average tumor size of 450 mm3), or 
remaining on the same olaparib treatment (5/9 mice 
with the average tumor size of 409 mm3). At the end of 
Figure 2: Steady state pharmacokinetics (PK) of niraparib and olaparib in tumor vs plasma. Tumor and plasma PK 
in the BRCA1mut MDA-MB-436 TNBC cell line-derived xenograft model (A & B) and BRCAwt OVC134 ovarian cancer PDX model 
(C & D) treated with niraparib (A & C) or olaparib (B & D) at the maximum tolerated dose. Niraparib and olaparib were administered at 75 
or 100 mg/kg once daily, respectively, in MDA-MB-436 model and 50 mg/kg once daily or 100 mg/kg twice daily, respectively in OVC134 
model. All mice from MDA-MB-436 model were treated for 5 days, and samples were collected on the last day of treatment at pre-dose and 
1, 2, 4, 8, 12, and 24 hours post dose for niraparib and at pre-dose and 0.5, 1, 2, 6, 12, and 24 hours post dose for olaparib. All mice from 
OVC134 model were treated for 2 days, and samples were collected on the last day of treatment at 1, 2, 4, 8, and 24 hours for niraparib and 
at 0.5, 1, 2, 6, and 12 hours for olaparib.
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the treatment on day 77, significant tumor regression 
was observed in the animals switched from olaparib 
to niraparib treatment in comparison to the animals 
continuing treatment on olaparib (P=0.05) (Figure 5). 
This result shows that the tumor response improved 
upon switching from olaparib to niraparib, suggesting 
either a concentration dependent effect, or an additional 
mechanism of action for niraparib in comparison to 
olaparib, or possibly both.
Niraparib is efficacious in an intracranial tumor 
model
To further understand if sustained brain exposure 
to niraparib could result in antitumor activity in brain 
tumor models, BALB/c nude mice were intracranially 
inoculated with the BRCA2mut Capan-1-luc tumor cells. 
The antitumor effects of daily niraparib treatment at 45 
mg/kg were compared with 75 mg/kg qd of olaparib, 
with both drugs administered at MTD. After 35 days of 
treatment, niraparib resulted in 62% TGI compared to 
-19% TGI for olaparib (Figure 6A, 6B, & Supplementary 
Figure 2C). The antitumor effects of niraparib at 45 mg/
kg qd and olaparib at 75 mg/kg qd were also tested in mice 
bearing subcutaneously inoculated Capan-1 tumor cells. 
Niraparib resulted in 53% TGI compared to 27% TGI for 
olaparib after 44 days of treatment (Figure 6C & 6D). 
None of the treatments induced significant body weight 
loss (data not shown). The differential anti-tumor effect of 
the two PARPi in the subcutaneous model suggested that 
this model maybe intrinsically more sensitive to niraparib. 
Notably, the niraparib efficacy in the intracranial model 
was similar to that in the subcutaneous model derived 
from the same cell line, suggesting that the brain exposure 
of niraparib is efficacious in this model. In comparison, 
the minimal effect of olaparib in the subcutaneous model 
was lost in the intracranial model, potentially due to its 
insufficient brain exposure.
Megakaryocyte toxicity is a class effect of PARPi 
in vitro
Clinically, niraparib treatment can result in 
thrombocytopenia in some patients. In this study, we 
observed that niraparib, in contrast to olaparib, distributed 
to bone marrow, where platelets are generated by 
megakaryocytes. We therefore evaluated the toxicity 
of PARPi on megakaryocytes differentiation in vitro. 
CD34+ cells were harvested from normal human bone 
marrow and differentiated into megakaryocytes. In this 
model system, the first 7 days of culture are dominated by 
proliferation of early progenitor cells, with differentiation 
and maturation occurring typically between day 7 and 10. 
Niraparib and olaparib were incubated with the CD34+ 
cells at 3 different concentrations throughout the course 
of the 10-day study, with 5-fluorouracil (5-FU) treatment 
serving as a positive control to evaluate its toxicity 
to megakaryocytes. Both drugs inhibited CD34+ cell 
proliferation, differentiation and maturation with similar 
potency on day 7 (niraparib IC50 = 1.2 μM; olaparib IC50 
= 1.6 μM) and day 10 (niraparib IC50 = 0.8 μM; olaparib 
IC50 = 1.3 μM), suggesting that the comparable toxicity to 
megakaryocyte lineage cells from both compounds, thus 
likely a class effect of PARPi (Supplementary Figure 5A 
& 5B). Greater bone marrow exposure associated with the 
high VD for niraparib may explain the thrombocytopenia 
observed with this agent at higher doses, with the 76-
fold higher exposure in tumor than bone marrow (Table 
3) rationalizing the large therapeutic window observed 
clinically. Bone marrow exposure to olaparib was not 
Table 3: Tissue Distribution of Niraparib and Olaparib
Model PARPi Tumor 
AUC0-last
(μg/g·h)
Brain 
AUC0-last
(μg/g·h)
Bone 
Marrow
AUC0-last 
(μg/g·h)
Plasma 
AUC0-last
(μg/
mL·h)
AUC0-last
Tumor:Plasma
AUC0-last
Brain:Plasma
AUC0-last
Tumor:Bone 
Marrow
MDA-
MB-436
Niraparib
(75 mg/kg qd 5 days) 213.96 18.72 2.82 65.08 3.3 0.29 75.9
Olaparib
(100 mg/kg qd 5 days) 7.59 0.34 LLOQ 11.28 0.7 0.03 ND
OVC134
Niraparib
(50 mg/kg qd 2 days) 83.14 8.31 - 25.50 3.3 0.33 -
Olaparib
(67 mg/kg bid 2 days) 9.73 0.45 - 15.59 0.6 0.03 -
AUC0–last=area under the plasma concentration–time curve from 0 to the time of the last PK sampling post-dose, for 
niraparib AUC0–last is AUC0–24h, for olaparib AUC0–last is AUC0–24h in MDA-MB-436 model and AUC0–12h in OVC134 model; 
LLOQ=lower limit of quantification; ND= not determined.
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observed in the same tumor model, consistent with the low 
tumor exposure relative to plasma potentially resulting 
from a low VD observed in preclinical and clinical settings.
DISCUSSION
This study compared niraparib and olaparib in 
terms of their pharmacokinetic properties and antitumor 
activities in several well characterized tumor xenograft 
models, and provides the first direct evidence that MTD 
administration of niraparib achieved higher exposures in 
tumor and some other tissues than olaparib. Consistent 
with its higher VD, niraparib tends to accumulate in 
tumor and other tissues rather than circulating in plasma, 
whereas olaparib tumor exposure is lower than plasma 
exposure. Niraparib also demonstrated significantly longer 
duration of exposure above efficacious concentration in 
the brain compared to olaparib. Together with the superior 
efficacy of niraparib observed in this study, our results 
demonstrate the importance of differential drug exposure 
and its association with antitumor activity, especially in 
BRCAwt and intracranial tumors.
Niraparib plasma AUC is also significantly higher 
than olaparib, even when olaparib is administered at higher 
daily dose, potentially due to the high bioavailability of 
niraparib. In addition, niraparib is not a substrate of the 
hepatic uptake transporters, OATP1B1 and OATP1B3, in 
particular, as well as the renal uptake transporters, such 
Figure 3: Effect of niraparib and olaparib on tumor volume and body weight in a BRCA1mut MDA-MB-436 TNBC cell line-derived 
xenograft model (A & B), BRCAwt OVC134 ovarian cancer PDX model (C & D), and BRCAwt A2780 ovarian cancer cell line-derived 
xenograft model (E & F). (A) Percentage change in body weight and (B) tumor volume of the MDA-MB-436 model treated with niraparib 
or olaparib at the maximum tolerated dose. Niraparib was administered at 75 mg/kg daily for 28 days. Olaparib was administered at 75 mg/
kg twice daily for 7 days and then at 67 mg/kg twice daily for 21 days due to significant body weight loss observed in the olaparib-treated 
group. (C) Tumor growth of the OVC134 model treated with niraparib or olaparib at the maximum tolerated dose. Dose reductions due to 
body weight loss are indicated in the chart below the growth curve for both the niraparib- and olaparib-treated groups. Two mice from each 
treated group were given extensive dose holidays and therefore were excluded from final analysis (D) Table summarizing TGI and P value 
calculated by Student’s t test for niraparib or olaparib compared to vehicle on day 40, *P<0.05, NS=not significant. (E) Tumor growth of 
A2780 xenograft model treated with niraparib or olaparib at the maximum tolerated dose. Niraparib and olaparib were administered at 62.5 
and 100 mg/kg daily, respectively. P value calculated by Student’s t test to compare niraparib and olaparib on day 9. (F) Table summarizing 
TGI and P value calculated by Student’s t test for niraparib or olaparib compared to vehicle on day 9, **P< 0.01, NS=not significant.
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as OAT1, OAT3, and OCT2 (data not shown). Therefore, 
there is minimal, if any, involvement of transporters in 
clearance/elimination of niraparib. In contrast, olaparib 
inhibits the hepatic drug uptake transporters OATP1B1 
and OCT1 as well as the renal uptake transporters OCT2 
and OAT3 [44], which may affect clearance of olaparib.
Notably, these results clearly indicate that niraparib 
and olaparib, which have similar in vitro PARP catalytic 
inhibition potency and cytotoxicity in BRCAmut cells [22] 
as well as in vivo efficacy in BRCAmut xenograft model, 
are not equivalent with respect to their effectiveness on 
tumor growth inhibition, particularly in BRCAwt models. 
Niraparib demonstrated greater efficacy compared 
to olaparib in vivo, a phenotype that could, at least 
partially, be attributed to their different pharmacokinetic 
properties, i.e. VD and cell permeability. This may also 
explain why niraparib has shown stronger activity in 
non-BRCAmut patients in clinical studies, as seen in 
the NOVA trial [23]. In this trial, niraparib treatment 
led to a 5.4-month improvement in the ovarian cancer 
patient without germline BRCA mutation. In comparison, 
olaparib delivered 1.9 months of PFS improvement in 
BRCAwt ovarian cancer patients in a Phase 2 clinical study 
(Study 19) [24]. Several previous in vitro studies have 
demonstrated that higher concentrations of PARPi are 
required to induce cell death in BRCAwt cells compared 
with BRCAmut cells [22, 45, 46]. Our results provide 
evidence that niraparib is effective in both OVC134 
(BRCAwt) and MDA-MB-436 (BRCAmut) tumor models, 
with a higher MED in BRCAwt tumors, suggesting that 
HR deficient tumors without BRCA mutation may require 
higher tumor PARPi concentrations to be efficacious.
To better mimic the clinical dosing schedule of 
olaparib, our experimental dose was optimized from 100 
mg/kg qd administered in MDA-MB-436 model to 67 mg/
kg bid in OVC134 model. However, possibly related to its 
relatively lower tumor exposure, bid dosing of olaparib 
did not result in meaningful antitumor efficacy (21% TGI) 
in the BRCAwt OVC134 model. The total daily doses of 
olaparib at MTD with qd and bid dosing remain similar, 
suggesting that dose and schedule change did not improve 
therapeutic window.
Although niraparib tumor exposure has yet to 
be reported in patients, such data will be important 
Figure 4: (A & B) Effect of different doses of niraparib on tumor volume in BRCA1mut MDA-MB-436 TNBC and BRCAwt OVC134 
ovarian xenograft models. Niraparib was administered at 25, 50, and 75 mg/kg once daily for 28 days in MDA-MB-436 model (A) or at 20 
and 40 mg/kg once daily, respectively, for 32 days and at 60 mg/kg once daily for 4 days and then at 50 mg/kg once daily for 28 days due 
to body weight loss observed in OVC134 model (B). One mouse from 40 mg/kg was excluded from final analysis due to extensive drug 
holiday applied to it, and 3 mice from 60 mg/kg treatment groups dead (B). (C) The correlation between percentage of TGI and doses used 
from Figure 4A & B and Figure 3B, 3C & 3D.
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for detailed interpretation of clinical performance. 
Pharmacokinetic modeling may also provide helpful 
information, especially when combined with observed 
clinical tumor concentration.
When attempted to correlate PARylation inhibition 
with antitumor effects in preclinical models, we noticed 
that inhibition of total PARylation is not a good biomarker 
for PARPi efficacy. Better assays need to be developed as 
tools for understanding PARPi activity in tumor models 
and clinical samples, such as PARP trapping assays or 
assays measuring substrate specific PARylation suitable 
for clinical sample analysis.
Even though both niraparib and olaparib are 
substrates of P-gp, the fact that niraparib can penetrate 
the BBB, where P-gp is highly expressed, suggests that 
niraparib might be able to overcome the efflux of P-gp 
potentially due to its high bio-membrane permeability. 
The relatively lower efflux rates compared to olaparib 
in P-gp and BCRP overexpressing cells observed in this 
study partially confirmed this hypothesis. More studies 
on specific mechanisms, such as directly measuring 
intracellular drug concentration, will provide more 
insights.
The brain exposure to niraparib was sustainable 
at the steady state in the tumor-free brain of OVC134 
model, with ≈4 μM at Cmax and ≈0.6 μM at trough. In 
contrast, although olaparib can penetrate the brain with 
≈2 μM at Cmax, it was eliminated from the brain quickly 
as its concentration dropped to 0.1 μM at 2 hours post 
dose and below the limit of detection at 6 hours post 
dose. The differences of brain exposure to niraparib 
and olaparib are more evident by their dose-normalized 
AUC ratios, 100- and 34-fold, in the MDA-MB-436 and 
OVC134 models, respectively. Clinical testing of such 
agents in brain tumors largely relies on a compromised 
BBB, a phenomenon related to late stage disease. On 
the contrary, agents that cross a competent BBB are 
required to control early stage brain malignancy and 
prevent brain metastasis from certain types of lung and 
breast cancers. Even though ovarian cancer-related brain 
metastases are relatively uncommon, the incidence rate 
has been reported to range from 0.49% to 11.54% with an 
average of 2.55% [47]. The therapeutic brain exposure to 
niraparib thus differentiates it from olaparib in preclinical 
models and merit to test niraparib in clinic against primary 
brain malignancy and clinical indications with high risk 
of brain metastases, such as lung and breast cancers. In 
addition, the ability of niraparib to penetrate the BBB not 
only reveals new opportunities for clinical development 
in brain malignancies, but also highlights the possibility 
of overcoming P-gp-induced drug resistance, as P-gp is 
highly expressed at BBB.
Figure 5: Effect of niraparib and olaparib on tumor volume in BRCA2mut OV5311 ovarian cancer PDX model. Tumor 
volume of the OV5311 model treated with niraparib or olaparib at the maximum tolerated dose. Niraparib was administered at 75 mg/kg 
daily for 78 days. Olaparib was administered at 75 mg/kg once daily for 44 days and then 4 mice from this group were switched to 50 mg/
kg of niraparib once daily for 34 days, while the remaining 5 mice continued with 75 mg/kg of olaparib.
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The synthetic lethality between PARPi and HR 
deficiency in tumor cells has been well established, but 
the lack of clinically suitable biomarker for identifying 
HR deficiency posts a challenge to clinical development 
of PARPi. Potential companion diagnostic tests have 
been developed, such as the myChoice HRD test (Myriad 
Genetics) and the fLOH test (Foundation Medicines), 
using genomic instability as biomarker for HR deficiency. 
However, these tests cannot identify all HR deficient 
patients, such as the ones with functional HR deficient 
tumors. Therefore, other approaches were also utilized to 
enrich HR deficient population in clinical development. 
For example, platinum response may enrich PARPi 
sensitive OC population, as HR deficient tumors and 
nucleotide excision repair deficient tumors are both 
sensitive to platinum treatment [48, 49].
In the NOVA trial (NCT01847274), the most 
common treatment-emergent adverse event leading 
to dose modification was thrombocytopenia, which 
was reversible and typically occurred during the first 
month of treatment. Dose modification of niraparib was 
shown to reduce the rate of thrombocytopenia with no 
reduction in efficacy [50]. While in vitro results from 
this study, consistent with what reported recently [51], 
suggested PARPi toxicity on megakaryocyte lineage 
cells, olaparib treatment induced thrombocytopenia 
and other hematological toxicities were not observed to 
the same extent as were seen with niraparib in clinical 
trials. One potential explanation could be the difference 
in tissue distribution including bone marrow exposure. 
As observed in our preclinical PK analysis, olaparib was 
undetectable in bone marrow, consistent with its low 
tumor exposure in preclinical models and low VD. While 
niraparib was detectable in bone marrow, which however 
was 76-fold lower than that in tumor, suggesting a large 
therapeutic window.
In summary, this study demonstrated, for the first 
time, the higher tumor and tissue exposure to niraparib 
compared to olaparib and associated correlation with 
enhanced antitumor activity in the xenograft animal 
models, especially in some BRCAwt tumors evaluated. 
More preclinical and clinical studies are clearly warranted 
to comprehend the potential of niraparib to benefit the 
patients with a variety of cancers.
Figure 6: Effect of niraparib and olaparib on tumor growth in intracranial BRCA2mut Capan-1-luc or subcutaneous 
Capan-1 pancreatic cancer xenograft model. (A) Tumor bioluminescent signals of the intracranial Capan-1-luc model treated with 
niraparib or olaparib. Niraparib or olaparib was administered at 45 or at 75 mg/kg daily, respectively, for 35 days. Two mice from control 
group were removed from data analysis since they were identified as the major outliers based on statistical analysis. One mouse from 
control or niraparib-treated group and two mice from olaparib-treated group died during treatment. (B) Table summarizing TGI and P value 
calculated by Student’s t test for niraparib or olaparib compared to vehicle on day 36, luc=luciferase; ***P< 0.001, NS=not significant. (C) 
Tumor growth of the subcutaneous Capan-1 model treated with niraparib or olaparib. Niraparib or olaparib was administered at 45 or at 
75 mg/kg daily, respectively, for 44 days. (D) Table summarizing TGI and P value calculated by Student’s t test for niraparib or olaparib 
compared to vehicle on day 44, ***P< 0.001, *P< 0.05.
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MATERIALS AND METHODS
Chemicals
Niraparib was synthesized in-house as described 
previously [52]. Olaparib was obtained from SelleckChem 
(Houston, TX). Niraparib was formulated in 0.5% methyl 
cellulose (Sigma-Aldrich, Shanghai, China) and olaparib 
was formulated in 10% DMSO (Sigma-Aldrich, Shanghai, 
China), 10% hydroxypropyl-β-cyclodextrin (Zibo Qianhui 
Biotechnology Co. Ltd., Shangdong, China) in PBS pH7.4 
(GE Healthcare Life Science, Logan, Utah).
Cell culture
A2780, MDA-MB-436, Capan-1 and Capan-1-luc 
cells were maintained in vitro as a monocultures at 37ºC in 
an atmosphere of 5% CO2 in air using RPMI1640 medium 
supplemented with 20% heat inactivated fetal bovine 
serum; L-15 medium supplemented with 10% fetal bovine 
serum, 10μg/mL insulin and 16μg/mL L-glutathione; 
IMDM medium supplemented with 20% FBS, 100 U/
mL penicillin and 100 μg/mL streptomycin, and 2 mM 
L-glutamine, respectively. The A2780 or MDA-MB-436 
tumor cells were routinely sub-cultured twice weekly by 
10μg/mL Insulin treatment or without any treatment. The 
Capan-1-luc cells were started at 5×105 viable cells/mL 
and sub-cultured at 1×106 cells/mL. Fresh growth medium 
(20% to 30% by volume) was added every 2 to 3 days. 
The cells growing in an exponential growth phase were 
harvested and counted for tumor inoculation.
In vitro A2780 cell cytotoxicity assays
A2780 cells were seeded in triplicate at densities 
of 105 per well for cytotoxicity assays in 96-well flat-
bottomed plates with the recommended culture medium. 
Cells were then incubated with either olaparib or niraparib 
for 6 days in recommended growth medium supplemented 
with 10% (v/v) FBS. Cell viability was assessed using 
MTT assays as previously described [53].
In vivo PK and efficacy studies
PK and efficacy studies in the orthotopic MDA-
MB-436 human cell line-derived breast cancer model, 
subcutaneous A2780 and OVCAR3 human cell line-
derived ovarian cancer models, and subcutaneous OV5308 
and OV5311 patient-derived ovarian cancer xenograft 
models were conducted at Crown Bioscience (Taicang, 
China or San Diego, USA). PK and efficacy studies 
in the OVC134 and OVC527 patient-derived ovarian 
cancer xenograft models and subcutaneous Capan-1 
and intracranial Capan-1-luc human cell line derived 
pancreatic cancer models were performed at Pharmaron, 
Inc. (Beijing, China). PK studies were conducted with 3 
mice at each timepoints. For efficacy studies, typically 6 
to 10 mice were randomized to each group. The protocol 
and any amendment(s) or procedures involving the 
care and use of animals in these studies were reviewed 
and approved by the Institutional Animal Care and Use 
Committee (IACUC) of Pharmaron or CrownBio prior 
to conduct. During the study, the care and use of animals 
was conducted in accordance with the regulations of 
the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC).
Seven- to 9-week-old female NOD/SCID mice 
(Beijing HFK Bio-Technology Co. Ltd., Beijing, China or 
Shanghai Lingchang Bio-Technology Co. Ltd., Shanghai, 
China) were inoculated at the right mammary fat pad with 
the MDA-MB-436 tumor cells (1 × 107) in 0.2 mL of 
phosphate-buffered saline (PBS) mixed with matrigel (1:1) 
for tumor development. For the A2780 or OVCAR3 tumor 
development, 6- to 8-week-old or 8- to 9-week-old female 
BALB/c Nude mice (Shanghai SIPPR-Bk Lab Animal Co. 
Ltd., Shanghai, China) were inoculated subcutaneously at 
the right flank with 5 × 106 tumor cells in 0.1 mL of PBS 
(1:1 mixed with matrigel) or with 1 × 107 tumor cells in 
0.1 mL of PBS (1:1 mixed with matrigel). 6- to 8-week-
old female NOD/SCID mice (Envigo Laboratories, USA) 
were inoculated at the rear flank with the OV5311 tumor 
cells (3 × 105) in 0.2 mL of PBS mixed with Cultrex 
ECM (1:1) or with OV5308 tumor cells (9 × 104) in 0.2 
mL of PBS mixed with Cultrex ECM (1:1) for tumor 
development. 6- to 8-week-old female BALB/c nude mice 
(Beijing AniKeeper Biotech Co. Ltd., Beijing, China) 
were inoculated subcutaneously on the right flank with a 
tumor fragment (2 mm × 2 mm × 2 mm) of the OVC134 
or OVC527 human primary ovarian cancer for tumor 
development. For the Capan-1 subcutaneous tumor model 
development, 6- to 8-week-old female BALB/c Nude mice 
were inoculated subcutaneously at the right flank with 
4 × 106 tumor cells in 0.1 mL of IMDM without serum 
(1:1 mixed with matrigel). For the Capan-1-luc tumor 
development, mice were anesthetized by intraperitoneal 
(IP) injection of ketamine/xylazine (90-120/5-10mg/
kg). The skins over the coronal and sagittal sutures were 
sterilized with iodine followed by alcohol. An incision 
of 0.5 cm was made along the skin over the midline to 
expose coronal and sagittal suture junctions. An inoculum 
of 2 × 105 Capan-1-luc tumor cells (in 2 μL IMDM) were 
injected into the right forebrain by positioning the needle 
at 2.0 mm lateral to the sagittal suture, 1.0 mm inferior to 
coronal suture with the injection depth precisely controlled 
at 3.0 mm. The injection was slowly proceeding over a 
one-minute period.
After tumor cell inoculation, the animals were 
checked daily for morbidity and mortality. At the time 
of routine monitoring, the animals were checked for any 
effects of tumor growth and treatments on normal behavior 
such as mobility, visual estimation of food and water 
consumption, body weight gain/loss (body weights were 
measured 2 to 3 times per week throughout the study), 
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eye/hair matting and any other abnormal effect. Any 
mortality and/or abnormal clinical signs were recorded.
Tumor volumes were measured 3 times weekly 
in 2 dimensions using a caliper, and the volume was 
expressed in mm3 using the formula: V = 0.5 a × b2 where 
a and b were the long and short diameters of the tumor, 
respectively. The entire procedures of dosing as well as 
tumor and body weight measurement were conducted in 
a Laminar Flow Cabinet. For the Capan-1-luc tumors, 
mice were injected intraperitoneally with D-luciferin 
of 7.5 mg/mL (at 10μl/g BW) and anesthetized with 
isoflurane inhalation. At 10 minutes after the luciferin 
injection, mice were imaged with an In Vivo Imaging 
System (IVIS, Xenogen/Caliper, USA). Bioluminescent 
signals (photons/s) from the region of interest (ROI) 
were quantified and used as an indicator of tumor growth. 
Tumor bioluminescent signals were conducted once a 
week. For PK studies, the treatment was started when 
the average tumor size reached approximately 320 to 360 
mm3. For the Capan-1-luc intracranial efficacy study, 
the treatment was started when the mean bioluminescent 
signal reaches approximately 5.5 × 106 photons/s. For all 
other efficacy studies, the treatment was started when 
the average tumor size reached approximately 50 to 200 
mm3. The tumor size was used for the calculation of tumor 
growth inhibition (TGI) = [1 - (T1-T0)/(C1-C0)] × 100, 
where C1= mean tumor volume of control mice at time 
t, T1 = mean tumor volume of treated mice at time t, C0 
= mean tumor volume of control mice at time 0, and T0 = 
mean tumor volume of treated mice at time 0.
Niraparib, olaparib, or vehicle (0.5% methyl 
cellulose) was administered orally once daily in the 
MDA-MB-436 PK, as well as A2780, OV5311, OVCAR3, 
Capan-1 and Capan-1-luc efficacy studies. Olaparib was 
administered orally twice daily in both OVC134 PK and 
efficacy studies, as well as the MDA-MB-436, OV5308, 
OVC527 efficacy studies as per Institutional Animal Care 
and Use Committee guidelines.
PK analysis of PARPi
Frozen tumor, brain, bone marrow, muscle 
and plasma samples were shipped to Charles River 
Laboratories (Agilux Laboratories, Inc, Worcester, MA) 
for bioanalytical sample analysis. Internal standard stock 
solution was prepared at 1 mg/mL in dimethyl sulfoxide. 
Internal standard spiking solution was prepared at 100 
ng/mL in 80:20 (v:v) water:acetonitrile. CD-1 mouse 
plasma (K2EDTA), pooled mixed gender, was purchased 
from BioChemed Services (Winchester, VA). The blank 
matrix was tested for interference at the retention time 
and mass transition of the analytes and internal standard, 
and was found to be free of significant interference. 
For niraparib, calibration standards were prepared on 
the day of sample extraction at concentrations of 1.00, 
2.50, 5.00, 20.0, 50.0, 100, 250, and 500 ng/mL niraparib 
in blank mouse plasma. Quality control samples were 
prepared at concentrations of 5.00, 50.0, and 250 ng/mL 
niraparib in blank mouse plasma. For olaparib, calibration 
standards were prepared on the day of sample extraction 
at concentrations of 1.00, 2.00, 5.00, 10.0, 50.0, 100, 500 
and 1000 ng/mL olaparib in blank mouse plasma. Quality 
control samples were prepared at concentrations of 5.00, 
50.0 and 500 ng/mL olaparib in blank mouse plasma. 
Plasma samples were not diluted prior to extraction. 
Tumor, muscle and brain samples were prepared for 
analysis by homogenization (on ice). After the samples 
were weighed, for every 1 g of tissue, 9 mL of 80:20 (v:v) 
water:acetonitrile was added to the sample. The samples 
were homogenized using a hand-held homogenizer. 
The dilution factor for the sample was 10. After 
homogenization, each sample was diluted by a factor of 5 
with blank mouse plasma, K2EDTA (10 μL of homogenate 
into 40 μL of plasma). The total dilution factor for the 
sample was 50. Bone marrow samples were diluted by 
a factor of 5 with blank mouse plasma, K2EDTA (10 
μL of sample into 40 μL of plasma). The dilution factor 
for the sample was 5. Niraparib and olaparib in the 
supernatants from plasma, brain, bone marrow, muscle 
and tumor samples were quantitatively determined using 
a qualified ultra-performance liquid chromatography 
with tandem mass spectrometric detection (UPLC-MS/
MS) (Agilent 1290 binary pump and a PAL HTC-XT 
autosampler, Applied Biosystems Sciex API 6500+ mass 
spectrometer). A Waters BEH C18 column (50 × 2.1 mm; 
1.7 μm) was used and maintained at 50°C during analysis. 
The instrument was equipped with an electrospray 
ionization source in positive-ion mode and the analytes 
were monitored in the multiple-reaction-monitoring scan 
mode. The calibration curve range for niraparib was 
1-500 ng/mL, and that for olaparib was 1-1000 ng/mL. 
The software application used to acquire and process the 
data for this study was Analyst® Version 1.6 (Applied 
Biosystems Sciex, Framingham, MA).
PK parameters for niraparib and olaparib were 
calculated using noncompartmental methods. The 
following parameters were determined in each animal, 
where possible, using Phoenix WinNonlin v7.0:
Cmax maximum observed plasma concentration that 
a drug achieves in a specified compartment.
tmax time of occurrence of Cmax.
AUC0-24h area under the plasma concentration 
versus time curve within time span 0 to 24 hours of post 
dose (C24hr), calculated by the linear trapezoidal rule.
Plasma concentrations were provided in units of 
ng/mL. PK parameters were determined using nominal 
sampling times. Dose normalized AUC0-lastwas derived 
after correcting concentrations to molar units using 
molecular weights of 320.39 and 434.46 Da for niraparib 
and olaparib, respectively, and then divided by total 
amount of drug used per 24 hours for niraparib or 12 hours 
for olaparib.
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Plasma concentrations below the lower limit of 
quantification of the assay (BLQ) were set zero if they 
occurred before the first measurable time point and were 
treated as missing if they occurred after the last measurable 
time point or in between 2 measurable time points.
In vitro liquid culture system to assess human 
megakaryocyte-specific development
In vitro human megakaryocyte differentiation was 
assessed using a liquid culture system in which the human 
bone marrow CD34+ cells (lot # 0150114, ReachBio) 
derived from normal bone marrow were used. X-Vivo 
15 (Lonza) containing 100 ng/mL SCF (Peprotech) and 
50 ng/mL Tpo was used to drive CD34+ cells proliferation 
and differentiation into megakaryocyte lineage cells. Test 
drugs were incubated with CD34+ cell for either 7 days or 
10 days. The megakaryocyte lineage cells characterized 
by an ability to exclude DAPI were analyzed by flow 
cytometry. The percentage of megakaryocyte lineage cells 
in the total CD34+ cells were then calculated. To determine 
the IC50 values, XLFit was used. The dose-response data 
for the relevant experimental conditions were tabulated 
and then processed using curve-fitting algorithm 205 
provided in XLFit.
In vitro human BCRP and MDR1 efflux (ABC) 
transporters assay
The monolayer assays were performed using 
parental and BCRP or MDR1 transfected MDCKII cell 
monolayers. MDCKII, MDCKII-BCRP and MDCKII-
MDR1 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium with 4.5 g/L glucose (DMEM) supplemented 
with 10% (v/v) fetal bovine serum (FBS) at 37 ± 1°C in 
an atmosphere of 95:5 air:CO2 in cell culture flasks prior 
to seeding into 24-transwell inserts (Corning). Transfected 
and parental MDCKII cells were cultured on the inserts 
with 100 μL medium per well on the apical side and 25 
mL in a single-well receiver tray for all 24 wells on the 
basolateral side, for 96 hours. Medium was changed 24 
hours before the experiment.
Permeability incubations were carried out in Hank’s 
Buffered Salt Solution (HBSS) at 37 ± 1°C. Apical to 
basolateral permeability of Lucifer Yellow (LY) was 
assessed as a low permeability control, LY was also 
incubated in the presence of the test articles (at the highest 
testing concentration: 100 μM) in order to assess the 
effect of the compounds on the monolayer integrity. LY 
samples (100 μL from basolateral wells) were analyzed by 
measuring fluorescence with the following wavelengths: 
excitation – 430 nm, emission – 520 nm. Trans-epithelial 
electric resistance (TEER) of each well was measured 
to confirm the confluency of the monolayers after the 
experiments.
The assays were conducted according to the actual 
SOLVO MDCKII-BCRP and MDCKII-MDR1 monolayer 
assay protocols (SOP).
Bidirectional transport of niraparib and olaparib 
was determined through control (parental or mock-
transfected), MDCKII-BCRP and MDCKII-MDR1 cell 
monolayers. Cells were pre-incubated in assay buffer for 
10 minutes to allow cells adjusting to the medium. Assay 
buffer containing the test articles (separately) at three 
concentrations (1 μM, 10 μM and 100 μM) was then added 
to the appropriate apical (100 μL) or basolateral (600 μL) 
chamber. The final concentration of the organic solvents in 
the incubations did not exceed 0.5% (v/v). The prazosin or 
digoxin efflux ratio was determined as a positive control 
for BCRP or MDR1 function, respectively.
After incubation at 37 ± 1°C for 120 minutes, 
aliquots (50 μL) were taken from the receiver chambers 
to determine the amount of translocated olaparib or 
niraparib and controls. Samples (50 μL) were also 
taken from the helper plate and donor chambers before 
and after incubation, respectively to determine the 
initial concentrations (C0) and recovery (R) of the test 
compounds and the controls. Bidirectional transport of 
the test articles in control, MDCKII-BCRP and MDCKII-
MDR1 cells was determined by LC-MS/MS.
poly(ADP-ribose) (PAR) formation 
pharmacodynamic study
Tumor was quickly collected, cut into pieces, 
weighed, snap frozen in liquid nitrogen and stored at -80ºC. 
Cell extracts were prepared from one piece of frozen 
tumors according to HT PARP in vivo Pharmacodynamic 
Assay II protocol (Trevigen, Gaithersburg, MD) at Crown 
Bioscience or at Pharmaron, Inc. Net PAR levels were 
determined in the MDA-MB-436 tumors or OVC134 
tumors collected immediately following 5 days or 2 days 
of treatment with either control, niraparib, or olaparib. 
Experimental samples and freshly made PAR standards 
were assayed in duplicate. The assay was repeated 
once for the niraparib-treated MDA-MB-436 tumors. 
PAR concentrations in the experimental samples were 
calculated using a standard curve, and PAR levels were 
normalized to the amount of total protein and reported as 
pg PAR per 100 μg of total protein. Concentration of the 
total protein in the extract was measured using the BCA 
Assay (Thermo Fisher Scientific, Waltham, MA).
Statistical analysis
Differences between values obtained in cell lines 
and tumors treated with different experimental conditions 
were determined using the Student’s t test on GraphPad 
Prism 7 (GraphPad Software). P< 0.05 was considered 
statistically significant.
Oncotarget37094www.oncotarget.com
Author contributions
KS, MK, ZW, and JW designed the studies; KS, 
MK, GP, GS and AV analyzed data; KS, MK, ZW and 
GP supervised CrownBio, Pharmaron, Agilux, SOLVO 
Biotechnology and ReachBio to perform the experiments; 
KS drafted the manuscript and JW revised the manuscript. 
All authors critically reviewed and approved the final 
version of the manuscript.
ACKNOWLEDGMENTS
The authors wish to acknowledge the contribution 
of Kenneth Thress, Kevin Coleman, and Hemant Vyas for 
critical review of the manuscript. This manuscript was 
developed with full author participation in accordance with 
Good Publication Practice 3 guidelines and International 
Committee of Medical Journal Editors guidelines. All 
authors had access to full data and analyses presented in 
this manuscript. Editorial support, funded by TESARO, 
Inc. (Waltham, MA, USA) and coordinated by Hemant 
Vyas, PhD of TESARO Inc., was provided by Mary 
Kay Lavy of Ashfield Healthcare Communications, 
Middletown, CT.
CONFLICTS OF INTEREST
KS, MK, ZW, GP, ZZ, JH, SR and JW are employees 
and/or shareholders of TESARO, Inc.
REFERENCES
1. Satoh MS, Lindahl T. Role of poly(ADP-ribose) 
formation in DNA repair. Nature. 1992; 356:356–58. 
https://doi.org/10.1038/356356a0.
2. De Vos M, Schreiber V, Dantzer F. The diverse roles and 
clinical relevance of PARPs in DNA damage repair: current 
state of the art. Biochem Pharmacol. 2012; 84:137–46. 
https://doi.org/10.1016/j.bcp.2012.03.018.
3. Krishnakumar R, Kraus WL. The PARP side of the 
nucleus: molecular actions, physiological outcomes, 
and clinical targets. Mol Cell. 2010; 39: 8-24. 
https://doi.org/10.1016/j.molcel.2010.06.017.
4. Eustermann S, Wu WF, Langelier MF, Yan g JC, Easton 
LE, Riccio AA, Pascal JM, Neuhaus D. Structural 
basis of detection and signaling of DNA single-strand 
breaks by human PARP-1. Mol Cell. 2015; 60:742–54. 
https://doi.org/10.1016/j.molcel.2015.10.032.
5. Purnell MR, Whish WJ. Novel inhibitors of poly(ADP-
ribose) synthetase. Biochem J. 1980; 185:775–77. 
https://doi.org/10.1042/bj1850775.
6. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami 
I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth 
A. BMN 673, a novel and highly potent PARP1/2 
inhibitor for the treatment of human cancers with DNA 
repair deficiency. Clin Cancer Res. 2013; 19: 5003-15. 
https://doi.org/10.1158/1078-0432.CCR-13-1391.
7. Zaremba T, Curtin NJ. PARP inhibitor development for 
systemic cancer targeting. Anticancer Agents Med Chem. 
2007; 7: 515-23.
8. Howlader NN, Krapcho M. SEER Cancer Statistics Review. 
National Cancer Institute. 1975–2014.
9. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, 
Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin 
AK, Gross J, Hartmann L, et al, and Cancer Genome 
Atlas Research Network. Integrated genomic analyses 
of ovarian carcinoma. Nature. 2011; 474:609–15. 
https://doi.org/10.1038/nature10166.
10. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel 
C, George J, Dobro vic A, Birrer MJ, Webb PM, Stewart 
C, Friedlander M, Fox S, Bowtell D, Mitchell G. 
BRCA mutation frequency and patterns of treatment 
response in BRCA mutation-positive women with 
ovarian cancer: a report from the Australian Ovarian 
Cancer Study Group. J Clin Oncol. 2012; 30:2654–63. 
https://doi.org/10.1200/JCO.2011.39.8545.
11. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, 
Rendi MH, Thornton A, Norquist BM, Casadei S, Nord 
AS, Agnew KJ, Pritchard CC, Scroggins S, et al. Germline 
and somatic mutations in homologous recombination genes 
predict platinum response and survival in ovarian, fallopian 
tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20: 
764-75. https://doi.org/10.1158/1078-0432.CCR-13-2287.
12. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, 
Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley 
K, Wilbanks G, Nicosia S, Cantor A, et al. BRCA1 and 
BRCA2 mutations account for a large proportion of 
ovarian carcinoma cases. Cancer. 2005; 104: 2807-16. 
https://doi.org/10.1002/cncr.21536.
13. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, 
Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li 
Y, Li J, Gonzalez-Angulo AM, et al. Somatic mutations 
in BRCA1 and BRCA2 could expand the number of 
patients that benefit from poly (ADP ribose) polymerase 
inhibitors in ovarian cancer. J Clin Oncol. 2010; 28: 3570-6. 
https://doi.org/10.1200/JCO.2009.27.2997.
14. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu 
X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, 
Gabrielson E, Schutte M, Baylin SB, Herman JG. Promoter 
hypermethylation and BRCA1 inactivation in sporadic 
breast and ovarian tumors. J Natl Cancer Inst. 2000; 
92:564–69. https://doi.org/10.1093/jnci/92.7.564.
15. Baldwin RL, Nemeth E, Tran H, Shvartsman H, 
Cass I, Narod S, Karlan BY. BRCA1 promoter region 
hypermethylation in ovarian carcinoma: a population-based 
study. Cancer Res. 2000; 60: 5329-33.
16. Konstantinopoulos PA, Ceccaldi R, Shapiro 
GI, D'Andrea AD. Homologous recombination 
deficiency: exploiting the fundamental vulnerability 
Oncotarget37095www.oncotarget.com
of ovarian cancer. Cancer Discov. 2015; 5: 1137-54. 
https://doi.org/10.1158/2159-8290.CD-15-0714.
17. Mendes-Pereira AM, Martin SA, Brough R, McCarthy 
A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth 
A. Synthetic lethal targeting of PTEN mutant cells with 
PARP inhibitors. EMBO Mol Med. 2009; 1: 315-22. 
https://doi.org/10.1002/emmm.200900041.
18. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, 
Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, 
Schulzer M, Chia S, et al. EMSY Links the BRCA2 pathway 
to sporadic breast and ovarian cancer. Cell. 2003; 115: 523-
35. https://doi.org/10.1016/S0092-8674(03)00930-9.
19. Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, 
Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen 
L, Kozarewa I, Assiotis I, et al. Genome-wide profiling 
of genetic synthetic lethality identifies CDK12 as a novel 
determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 
2014; 74: 287-97. https://doi.org/10.1158/0008-5472.
CAN-13-2541.
20. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati 
P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen 
K, Weinstock DM, Gorospe M, Harris AL, Helleday 
T, Chowdhury D. miR-182-mediated downregulation 
of BRCA1 impacts DNA repair and sensitivity 
to PARP inhibitors. Mol Cell. 2011; 41:210–20. 
https://doi.org/10.1016/j.molcel.2010.12.005.
21. Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian 
cancer-associated mutations disable catalytic activity of 
CDK12, a kinase that promotes homologous recombination 
repair and resistance to cisplatin and poly(ADP-ribose) 
polymerase inhibitors. J Biol Chem. 2014; 289: 9247-53. 
https://doi.org/10.1074/jbc.M114.551143.
22. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow 
JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and 
PARP2 by clinical PARP inhibitors. Cancer Res. 2012; 72: 
5588-99. https://doi.org/10.1158/0008-5472.CAN-12-2753.
23. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, 
Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, 
Ben-Baruch NE, Marth C, Mądry R, et al, and ENGOT-OV16/
NOVA Investigators. Niraparib maintenance therapy in 
platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 
2016; 375:2154–64. https://doi.org/10.1056/NEJMoa1611310.
24. Ledermann J, Harter P, Gourley C, Friedlander M, 
Vergote I, Rustin G, Scott CL, Meier W, Shapira-
Frommer R, Safra T, Matei D, Fielding A, Spencer S, et 
al. Olaparib maintenance therapy in patients with platinum-
sensitive relapsed serous ovarian cancer: a preplanned 
retrospective analysis of outcomes by BRCA status in a 
randomised phase 2 trial. Lancet Oncol. 2014; 15:852–61. 
https://doi.org/10.1016/S1470-2045(14)70228-1.
25. Ashworth A. A synthetic lethal therapeutic approach: 
poly(ADP) ribose polymerase inhibitors for the 
treatment of cancers deficient in DNA double-
strand break repair. J Clin Oncol. 2008; 26: 3785-90. 
https://doi.org/10.1200/jco.2008.16.0812.
26. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda 
S, Morris J, Teicher B, Doroshow JH, Pommier Y. 
Stereospecific PARP trapping by BMN 673 and comparison 
with olaparib and rucaparib. Mol Cancer Ther. 2014; 13: 
433-43. https://doi.org/10.1158/1535-7163.MCT-13-0803.
27. Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill 
cancer cells: PARP inhibitors and their mechanisms of action. 
Sci Transl Med. 2016; 8:362ps17.
28. Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, 
Strauss R, Bartek J. High speed of fork progression induces 
DNA replication stress and genomic instability. Nature. 2018; 
559: 279-84. https://doi.org/10.1038/s41586-018-0261-5.
29. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier 
GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 
2010; 10: 293-301. https://doi.org/10.1038/nrc2812.
30. Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, 
Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung 
S, Rutka JT, Taylor MD, Dirks PB, Hawkins C. Poly-ADP-
Ribose polymerase as a therapeutic target in pediatric 
diffuse intrinsic pontine glioma and pediatric high-
grade astrocytoma. Mol Cancer Ther. 2015; 14:2560–68. 
https://doi.org/10.1158/1535-7163.MCT-15-0282.
31. Engert F, Schneider C, Weibeta LM, Probst M, Fulda 
S. PARP inhibitors sensitize ewing sarcoma cells to 
temozolomide-induced apoptosis via the mitochondrial 
pathway. Mol Cancer Ther. 2015; 14: 2818-30. 
https://doi.org/10.1158/1535-7163.Mct-15-0587.
32. Michelena J, Lezaja A, Teloni F, Schmid T, Imhof R, 
Altmeyer M. Analysis of PARP inhibitor toxicity by 
multidimensional fluorescence microscopy reveals 
mechanisms of sensitivity and resistance. Nat Commun. 
2018; 9:2678. https://doi.org/10.1038/s41467-018-05031-9.
33. Pharmacology Noc. https://www.accessdata.fda.gov/
drugsatfda_docs/nda/2014/206162Orig1s000ClinPha
rmR.pdf.
34. EMA Z. http://www.ema.europa.eu/docs/en_GB/document_
library/EPAR_-_Public_assessment_report/human/004249/
WC500239291.pdf.
35. Review ONC. https://www.accessdata.fda.gov/drugsatfda_
docs/nda/2014/206162Orig1s000ChemR.pdf.
36. EMA O. http://www.ema.europa.eu/docs/en_GB/document_ 
library/EPAR_-_Public_assessment_report/human/003726/
WC500180154.pdf.
37. van Andel L, Rosing H, Zhang Z, Hughes L, Kansra 
V, Sanghvi M, Tibben MM, Gebretensae A, Schellens 
JHM, Beijnen JH. Determination of the absolute oral 
bioavailability of niraparib by simultaneous administration 
of a (14)C-microtracer and therapeutic dose in cancer 
patients. Cancer Chemother Pharmacol. 2018; 81: 39-46. 
https://doi.org/10.1007/s00280-017-3455-x.
38. label O. https://www.accessdata.fda.gov/drugsatfda_docs/
label/2017/208558s000lbl.pdf.
39. Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov 
V, McCormack P, Swaisland H, Cavallin M, Parry T, 
Oncotarget37096www.oncotarget.com
Carmichael J, Dixon JM. Evaluation of the pharmacodynamics 
and pharmacokinetics of the PARP inhibitor olaparib: a 
phase I multicentre trial in patients scheduled for elective 
breast cancer surgery. Invest New Drugs. 2013; 31: 949-58. 
https://doi.org/10.1007/s10637-012-9922-7.
40. NDA_pharmacology O. https://www.accessdata.fda.gov/
drugsatfda_docs/nda/2014/206162Orig1s000PharmR.pdf.
41. Minchinton AI, Tannock IF. Drug penetration in 
solid tumours. Nat Rev Cancer. 2006; 6: 583-92. 
https://doi.org/10.1038/nrc1893.
42. Lawlor D, Martin P, Busschots S, Thery J, O'Leary 
JJ, Hennessy BT, Stordal B. PARP Inhibitors as 
P-glyoprotein substrates. J Pharm Sci. 2014; 103: 1913-20. 
https://doi.org/10.1002/jps.23952.
43. label N. https://www.accessdata.fda.gov/drugsatfda_docs/
label/2017/208447lbl.pdf.
44. McCormick A, Swaisland H. In vitro assessment of the 
roles of drug transporters in the disposition and drug–drug 
interaction potential of olaparib. Xenobiotica. 2017; 47: 
903-15. https://doi.org/10.1080/00498254.2016.1241449.
45. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, 
Richardson TB, Santarosa M, Dillon KJ, Hickson I, 
Knights C, Martin NM, Jackson SP, Smith GC, Ashworth 
A. Targeting the DNA repair defect in BRCA mutant 
cells as a therapeutic strategy. Nature. 2005; 434:917–21. 
https://doi.org/10.1038/nature03445.
46. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, 
Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific 
killing of BRCA2-deficient tumours with inhibitors of 
poly(ADP-ribose) polymerase. Nature. 2005; 434: 913. 
https://doi.org/10.1038/nature03443.
47. Pakneshan S, Safarpour D, Tavassoli F, Jabbari 
B. Brain metastasis from ovarian cancer: a 
systematic review. J Neurooncol. 2014; 119: 1-6. 
https://doi.org/10.1007/s11060-014-1447-9.
48. Wozniak K, Blasiak J. Recognition and repair of DNA-
cisplatin adducts. Acta Biochim Pol. 2002; 49:583-96.
49. Zhang N, Liu X, Li L, Legerski R. Double-strand breaks 
induce homologous recombinational repair of interstrand 
cross-links via cooperation of MSH2, ERCC1-XPF, REV3, 
and the Fanconi anemia pathway. DNA Repair (Amst). 2007; 
6: 1670-8. https://doi.org/10.1016/j.dnarep.2007.06.002.
50. Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, 
Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten 
O, Ledermann J, Pineda M, Ellard S, et al. Safety and dose 
modification for patients receiving niraparib. Ann Oncol. 2018; 
29: 1784-1792. https://doi.org/10.1093/annonc/mdy181.
51. Leo E, Johannes J, Illuzzi G, Zhang A, Hemsley P, Bista MJ, 
Orme JP, Talbot VA, Narvaez AJ, Underwood E, Pike A, 
Nikkila JK, Riches L, et al. Abstract LB-273: A head-to-head 
comparison of the properties of five clinical PARP inhibitors 
identifies new insights that can explain both the observed 
clinical efficacy and safety profiles. Cancer Res. 2018; 78: 
LB-273. https://doi.org/10.1158/1538-7445.AM2018-LB-273.
52. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, 
Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale 
MV, Palumbi MC, Pesci S, Roscilli G, et al. Discovery 
of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-
carboxamide (MK-4827): a novel oral poly(ADP-ribose)
polymerase (PARP) inhibitor efficacious in BRCA-1 
and -2 mutant tumors. J Med Chem. 2009; 52: 7170-85. 
https://doi.org/10.1021/jm901188v.
53. Vaidyanathan A, Sawers L, Gannon AL, Chakravarty 
P, Scott AL, Bray SE, Ferguson MJ, Smith G. ABCB1 
(MDR1) induction defines a common resistance 
mechanism in paclitaxel- and olaparib-resistant 
ovarian cancer cells. Br J Cancer. 2016; 115:431–41. 
https://doi.org/10.1038/bjc.2016.203.
